Business Context and Reporting Period
This Form 6-K filing by Smith & Nephew plc is dated September 30, 2025. The document serves as a report of a foreign private issuer regarding the relocation of its Chief Financial Officer (CFO), John Rogers, from the United Kingdom to the United States, effective September 29, 2025. Smith & Nephew is a global medical technology business operating in approximately 100 countries with three business units: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company generated annual sales of $5.8 billion in 2024.
Key Financial Metrics
The filing does not provide current period revenue, profit, cash flow, margins, debt, or liquidity metrics. The only historical financial figure cited is the 2024 annual sales of $5.8 billion. The document focuses on executive compensation adjustments rather than corporate financial performance.
Material Changes
The primary material change disclosed is the relocation of the CFO to the United States to align with the region's contribution of over half of the Group's revenue. Associated changes include:
- Base Salary: Reduced from £750,375 (approx. $1,013,006) to $875,000.
- Pension Cash Allowance: Reduced from 12% to 7.5% of base salary.
- Target Bonus: Remains unchanged at 107.5% of base salary.
- Performance Share Plan (PSP): Target award increases from 137.5% to 150% of base salary (effective January 1, 2026).
- Restricted Share Plan (RSP): New eligibility for an annual award of 125% of base salary.
Guidance, Outlook, and Risks
Management Commentary: The relocation is intended to enhance executive leadership and oversight in the US market, which is a major contributor to future growth. The CFO will continue to spend significant time at the global headquarters in the UK.
Risks and Contingencies: The filing includes a standard forward-looking statement disclaimer. Identified risks include conflicts in Europe and the Middle East, economic conditions affecting healthcare payers, regulatory approvals, product defects, supply chain disruptions, cybersecurity, and foreign exchange volatility.
Unusual Items: The filing includes a notification under the UK Market Abuse Regulation regarding the grant of 41,360 ordinary shares to the CFO under the Restricted Share Plan 2024 on September 29, 2025. These shares vest in three equal tranches in March 2026, 2027, and 2028.
Investor Verification Checklist
- Verify the impact of the CFO's relocation on US operational oversight and strategic execution.
- Confirm the details of the new US employment contract and remuneration alignment with local market practices.
- Review the vesting conditions for the 41,360 restricted shares granted to the CFO.
- Monitor the company's 20-F annual report for updated financial performance data, as this 6-K does not contain current period financial results.
- Assess the potential impact of the listed geopolitical and regulatory risks on the company's global supply chain and revenue streams.